Zithromax
Zithromax Price range: $ 40,00 through $ 865,00
Back to products
Zocor
Zocor Price range: $ 30,00 through $ 361,00

Zocitab

Price range: $ 201,00 through $ 788,00

Zocitab is a highly effective medication specifically designed to prevent the development of gastric ulcers. It is primarily utilized by individuals who require long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) for various chronic conditions. The active components in Zocitab work by significantly reducing the amount of acid produced in the stomach. Additionally, it helps protect the stomach lining by replacing natural protective substances that are often depleted by regular painkiller use. This dual action ensures a safer experience for the digestive system while managing ongoing inflammatory symptoms.

Active substance: Capecitabine
SKU: Zocitab Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Zocitab belongs to the class of antineoplastic antimetabolites utilized in oncology regimens to inhibit abnormal cellular proliferation. As a prescription-only therapy regulated by the FDA, this medication requires precise dosing and ongoing medical oversight by a qualified healthcare professional.

This informative overview details the therapeutic mechanism, administration considerations, potential adverse effects, and critical safety precautions associated with Zocitab treatment in the United States.

Clinical Profile and Usage Guidelines

Main uses

Zocitab is indicated as a prescription treatment for specific malignant neoplasms, primarily colorectal cancer and locally advanced or metastatic breast cancer, depending on the therapeutic protocol established by an oncologist. In clinical practice, it may be prescribed as monotherapy or in combination with other cytostatic agents to suppress tumor progression. Any use outside of FDA-approved oncology indications represents off-label prescribing and must be determined strictly by a licensed practitioner based on individualized patient assessment and clinical guidelines.

How the drug works

Zocitab functions as an antimetabolite prodrug that undergoes systemic enzymatic conversion into active fluorouracil metabolites within tissue cells. The active metabolite interferes with DNA synthesis and inhibits cell division by integrating false pyrimidine bases into cellular RNA and DNA, alongside inhibiting the enzyme thymidylate synthase. Because rapidly dividing neoplastic cells exhibit high rates of nucleic acid synthesis, they demonstrate increased susceptibility to the cytotoxic effects of these metabolites, leading to impaired tumor growth and apoptosis.

Dosing schedule

The dosage of Zocitab is calculated individually based on the patient’s body surface area (expressed in square meters) and specific oncological protocols. Administrations are typically organized into repeated treatment cycles, comprising days of active administration followed by resting periods to facilitate recovery of normal tissues. Oral formulations should be taken with water within 30 minutes following a meal to optimize systemic absorption and minimize gastric distress. Adjustments to the dose or treatment interruptions may be necessary if moderate to severe organ toxicities arise during therapy.

What happens in the body

Following oral administration, Zocitab is readily absorbed through the gastrointestinal tract and rapidly metabolized in the liver and tissue cells. Peak plasma concentrations of the precursor compound occur relatively quickly, followed by enzymatic transformations via carboxylesterase and cytidine deaminase into intermediary compounds. Final conversion to active fluorouracil takes place preferentially within tumor tissues expressing high concentrations of thymidine phosphorylase. Metabolites are primarily eliminated through renal excretion, with a small portion excreted via respiratory and fecal pathways.

If you skip a dose

If a scheduled dose of Zocitab is missed, the patient should skip the missed dose and resume the normal dosing schedule at the next designated time. Patients must never double the dose or take extra medication to make up for a missed administration, as this increases the risk of acute drug toxicity. The prescribing physician or oncology clinic should be informed of missed doses for tracking protocol adherence.

Safety, Interactions, and Frequently Asked Questions

Adverse reactions

Treatment with Zocitab may produce adverse reactions across multiple organ systems. Commonly observed adverse events include gastrointestinal symptoms such as nausea, diarrhea, vomiting, stomatitis, and abdominal pain. Dermatological reactions, notably hand-foot syndrome (palmar-plantar erythrodysesthesia), may manifest as redness, swelling, numbness, or pain on the palms and soles. Hematologic toxicities, including neutropenia, anemia, and thrombocytopenia, require routine blood count monitoring. Patients experiencing persistent or worsening side effects should notify their medical team promptly.

Compatibility with other medicines

Zocitab interacts with several drug classes, potentially altering therapeutic efficacy or increasing toxicity risks. Co-administration with oral anticoagulants, such as warfarin, can significantly prolong clotting parameters and increase the risk of severe bleeding, necessitating frequent monitoring of International Normalized Ratio (INR). Concomitant use of phenytoin may result in elevated plasma phenytoin levels and associated toxicity. Additionally, live vaccines should be avoided during therapy due to drug-induced immunosuppression, which reduces immune response efficacy and elevates infection risk.

Important precautions

Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency are at heightened risk for life-threatening or fatal toxicities when receiving pyrimidine analogs like Zocitab. Renal and hepatic function must be evaluated prior to initiating therapy, as dosage adjustments or treatment avoidance may be necessary in severe impairment. Myelosuppression and cardiotoxicity, including myocardial infarction or angina, represent serious potential complications requiring immediate therapeutic intervention and continuous monitoring throughout the treatment regimen.

Special populations

Zocitab is contraindicated during pregnancy due to demonstrated risks of fetal harm and teratogenicity. Women of reproductive potential and male patients with female partners of reproductive potential must utilize effective contraception during treatment and for a specified period following the final dose. Breastfeeding should be discontinued during therapy. Pediatric safety and efficacy have not been established. Elderly patients may experience heightened sensitivity to drug toxicities, requiring cautious dosing.

Red flags

Immediate emergency medical care is required if severe adverse symptoms occur during Zocitab therapy. Warning signs include severe chest pain or irregular heartbeat, sudden difficulty breathing, swelling of the face, tongue, or throat, unmanageable diarrhea leading to dehydration, high fever accompanied by chills, or unusual bleeding and bruising. Prompt clinical intervention is crucial to manage life-threatening complications effectively.

Emergency Warning Sign Recommended Action
Swelling of face, lips, tongue, or difficulty breathing Seek immediate emergency care (Call 911)
Chest pain, tightness, or irregular heartbeat Seek emergency evaluation immediately
Severe diarrhea (4+ extra stools per day) Contact oncology team immediately; hydration needed
High fever (100.4°F / 38°C or higher) with chills Contact provider immediately for neutropenic evaluation
Unusual bleeding, bruising, or black tarry stools Report to physician immediately

Storage and expiration

Zocitab should be stored at controlled room temperature, typically between 68°F to 77°F (20°C to 25°C), away from excess moisture, heat, and direct sunlight. Keep the container tightly closed and out of reach of children and pets. Do not use the medication beyond the expiration date printed on the packaging. Unused or expired cancer medications should be disposed of via designated pharmacy take-back programs rather than household waste.

Common questions

How should hand-foot syndrome be managed during Zocitab treatment?

Hand-foot syndrome (palmar-plantar erythrodysesthesia) presents as redness, swelling, tenderness, or peeling on the palms of the hands and soles of the feet. Patients should apply non-medicated moisturizing creams, avoid friction, wear comfortable footwear, and prevent exposure to hot water. If skin changes interfere with daily activities or cause pain, the healthcare provider should be notified immediately, as temporary dose modification or interruption may be necessary.

Is routine blood testing necessary while taking Zocitab?

Yes, routine laboratory testing is essential throughout Zocitab therapy. Periodic complete blood counts (CBC) monitor white blood cells, red blood cells, and platelets to detect myelosuppression early. Furthermore, renal function tests and liver function panels are routinely performed to ensure safe drug metabolism and excretion.

Can Zocitab be taken with alcohol or specific foods?

Zocitab must be swallowed with water within 30 minutes following a meal to ensure appropriate pharmacokinetics and limit gastrointestinal upset. Alcohol consumption should be discussed with the prescribing oncologist, as alcohol can exacerbate mucosal irritation, increase dehydration risk, and add metabolic strain on the liver.

What should be done if severe diarrhea occurs during therapy?

Severe diarrhea is a major potential side effect that requires prompt clinical attention. Patients experiencing four or more bowel movements per day over their baseline should contact their oncology team immediately. Rehydration protocols and prescribed anti-diarrheal medications should be initiated under medical guidance, and dosing may need to be paused until symptoms resolve.

Property Details
Therapeutic class Antineoplastic agent (Pyrimidines / Nucleoside Metabolic Inhibitor)
Dosage form Oral tablet
Route of administration Oral
Prescription status Prescription-only (Rx)
Primary purpose Treatment of specific advanced solid tumors
Administration timing Within 30 minutes after a meal
Storage conditions Controlled room temperature (68°F–77°F)

This text is for informational purposes only and does not constitute individual medical advice.

In accordance with FDA requirements.

Additional information
Dosage

500mg

Package

10 pills

,

20 pills

,

30 pills

,

40 pills

,

50 pills

Ενεργός Ουσία